Salt Intake and Blood Pressure Control in Adults With Essential Hypertension
NCT ID: NCT07025928
Last Updated: 2025-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
190 participants
INTERVENTIONAL
2025-07-01
2030-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This three-part study will involve adults aged 21 years and above, with a self-reported diagnosis of hypertension for at least six months and/or currently taking antihypertensive medication. Participants will be recruited from two SingHealth Polyclinics (Punggol Polyclinic and Pasir Ris Polyclinic). Healthcare providers (HCPs) working at these clinics who have experience in managing patients with hypertension and in educating patients on reducing dietary sodium intake will also be recruited.
The main questions this study aims to answer are:
* What are the perceived barriers and facilitators for patients with hypertension to reduce dietary sodium and increase potassium intake?
* What are the perceived barriers and facilitators experienced by healthcare providers in educating patients about sodium reduction and potassium intake?
* Is the DSHP Diet Tool feasible and effective in reducing dietary sodium intake and increasing potassium intake among patients with hypertension?
Participants in the intervention group will be provided DSHP Diet Tool and Decreased Salt High Potassium patient information leaflet (DSHP PIL). Participants in the control group will receive standard care and a patient information leaflet (DSHP PIL). Researchers will compare participants in the intervention group to the control group to determine whether the DSHP tool is effective in reducing dietary sodium and increasing potassium intake in patients with hypertension.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Salt Reduction on Blood Pressure and Cardiovascular Organ Damage
NCT00152074
Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)
NCT00000608
China Salt Substitute Study
NCT00145756
Effects of Potassium Salts on Blood Pressure and Target Organ Damage
NCT00160368
Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health
NCT02972619
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Excess sodium elevates blood pressure by causing fluid retention and adversely affecting vascular function. Conversely, potassium intake helps regulate blood pressure through mechanisms like promoting sodium excretion and reducing vascular resistance. The benefits of dietary sodium reduction and increasing potassium intake are well-established in both clinical trials and population studies, particularly in individuals with hypertension.
Despite this, Singaporeans continue to consume well above the recommended daily intake for sodium and below the optimal levels for potassium. The average sodium intake is approximately 3,620 mg/day (exceeding the WHO recommendation of 2,000 mg/day), while potassium intake averages 2,500 mg/day (below the recommended 3,510 mg/day). Public health initiatives like the "War on Salt" campaign (launched in 2011) have had limited long-term success in addressing these dietary gaps.
Previous studies in Singapore and neighboring countries have identified significant gaps in knowledge, attitudes, and behaviors related to dietary sodium and potassium. However, there has been limited research focused on practical, context-specific educational interventions aimed at improving dietary behaviors related to salt and potassium intake, especially within the hypertensive population in the primary care setting.
Study Objectives and Hypothesis This study is designed in three parts to systematically develop, refine, and evaluate a novel educational tool-the Decreased Salt High Potassium (DSHP) Diet Tool-for hypertensive patients. The tool aims to support patients in reducing dietary sodium and increasing potassium intake, thereby improving blood pressure control and overall cardiovascular risk profiles.
Primary Hypothesis: A targeted educational tool, developed based on patient and healthcare provider input, will be feasible and effective in supporting reductions in sodium intake and increases in potassium intake among hypertensive patients, leading to improved blood pressure outcomes.
Objectives:
Part 1:
* Identify perceived barriers, facilitators, and attitudes towards reduced sodium and increased potassium diets among hypertensive patients.
* Understand healthcare providers' (HCPs) perspectives on the barriers in educating patients about reducing sodium intake and increasing potassium intake.
Part 2:
* Develop a prototype DSHP Diet Tool based on findings from Part 1.
* Alpha-test the tool with both patients and HCPs to assess usability and acceptability.
* Refine the tool through multiple feedback cycles using qualitative interviews and usability surveys (System Usability Scale - SUS).
Part 3:
\* Conduct a pilot randomized controlled trial (RCT) to evaluate the feasibility, usability, and preliminary effectiveness of the DSHP Diet Tool in real-world clinical settings.
Study Design Overview
The study will be conducted in three distinct but interrelated parts:
Part 1: Qualitative study
Design: Qualitative study using in-depth interviews and/or focus group discussions guided by the Theoretical Domains Framework (TDF). Population: 40 hypertensive patients and 20 healthcare providers from two SingHealth Polyclinics (Punggol and Pasir Ris). Sampling: Purposive sampling to ensure diversity in age, gender, ethnicity in patients Data Collection:
\* Audio-recorded, semi-structured interviews will be carried out Data Analysis: Thematic analysis using the TDF as a guiding framework. Coding will be conducted independently by multiple researchers to ensure reliability. Data collection will continue until saturation is achieved.
Part 2: Development and Alpha Testing of DSHP Diet Tool
Design: Mixed-methods developmental study. Tool Development: Content developed using findings from Part 1 and validated through collaboration with dietitians, nurses, content experts, and HCPs. Components include:
* General education on sodium and potassium.
* Sodium intake calculator and tracker.
* Food lists and risk matrix.
* Behavior change strategies and goal setting.
* Progress tracking and support resources.
Alpha Testing:
* 20 hypertensive patients and 20 HCPs will test the tool over four iterative cycles (5 patients and 5 HCPs per round).
* Participants will use the DSHP Tool for two weeks.
* Feedback collected via System Usability Scale (SUS) and semi-structured interviews.
* DSHP Tool will be revised based on feedback from each cycle.
Outcome Measures:
* SUS scores (target usability score ≥ 68).
* Feedback on usability and feasibility of the DSHP Tool
Part 3: Pilot Randomized Controlled Trial (RCT) Design: Parallel, two-arm, 1:1 allocation pilot RCT with mixed-method evaluation. Sites: SingHealth Polyclinic - Punggol and SingHealth Polyclinic - Pasir Ris. Sample Size: 80 patients with hypertension (40 per arm), with 25% over-recruitment to account for attrition. Randomization: Using sealed, sequentially numbered opaque envelopes (SNOEs) prepared by an independent researcher. Duration: 24-week intervention period.
Arms:
* Intervention Group: DSHP Tool + Patient Information Leaflet (PIL).
* Control Group: Standard care + PIL.
Assessments (Baseline and 24 weeks):
* Blood pressure (systolic/diastolic)
* Body weight and height
* Serum sodium, potassium, creatinine
* 24-hour urinary sodium and potassium
* Salt literacy and DASH adherence scores
Qualitative Component: At the end of the RCT, a subset of patients from the intervention group will participate in interviews to provide in-depth feedback on acceptability, usability of the DSHP Tool.
Statistical Methods
Quantitative Analysis:
* Independent t-tests or Wilcoxon rank-sum tests for group comparisons.
* Paired t-tests or Wilcoxon signed-rank tests for within-group comparisons.
* Categorical variables analyzed using chi-square tests.
* Intention-to-treat (ITT) principles will be used.
* Missing data managed via multiple imputation or last observation carried forward.
Qualitative Analysis:
* Framework analysis based on TDF.
* Coding verified by multiple investigators.
* Triangulation with quantitative data for integrated interpretation.
Ethical Considerations and Safety
* The study has obtained approval from the SingHealth Centralised Institutional Review Board (CIRB).
* Written informed consent will be obtained from all participants.
* Participants may withdraw at any time without penalty.
* All data will be de-identified and stored securely.
* Risks include potential discomfort during interviews or dietary changes, and rare risks such as hyperkalemia or hyponatremia. Patients at risk of hyperkalemia or hyponatremia are excluded from participation.
Expected Impact and Significance
This study aims to address critical gaps in dietary management of hypertension in Singapore by:
* Developing a practical, theory-informed, user-centered dietary tool.
* Empowering patients to self-manage their hypertension through improved dietary habits.
* Supporting HCPs with an effective educational resource.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DSHP Diet Tool and DSHP Patient information leaflet
Participants in this arm will receive standard hypertension care along with access to the Decreased Salt High Potassium (DSHP) Diet Tool for 24 weeks and DSHP Patient information leaflet. The DSHP Tool is a patient-centered educational resource developed to support sodium reduction and increase potassium intake through practical strategies, goal setting, and food guidance. Participants will also receive the DSHP Patient Information Leaflet (PIL). Patients will be guided on how to use the tool by a study coordinator. Clinical and dietary assessments will be conducted at baseline and at the end of the intervention.
Decreased Salt High Potassium Tool (DSHP Tool)
Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .
Standard Care + DSHP Patient Information Leaflet
Participants in this arm will receive standard hypertension care as provided at SingHealth Polyclinics, along with the DSHP Patient Information Leaflet (PIL). The PIL provides written guidance on reducing sodium and increasing potassium intake. No access to the DSHP Tool will be provided in this arm. Participants will undergo the same clinical and dietary assessments as the intervention group at baseline and after 24 weeks.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Decreased Salt High Potassium Tool (DSHP Tool)
Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who self-reports to have hypertension for at least six months and/ or taking at least one type of antihypertensive medication daily for at least six months
* Able to read English
* HCPs who had prior experience in advising patients on dietary salt reduction
* HCPs who self-reported to have ever treated patients with hypertension
Exclusion Criteria
* Participants with CKD stage 3B and above
* Participants with serum potassium of above 4.5mmol/L (on the latest blood test)
* Participants with serum sodium of less than 135 mmol/L (on the latest blood test)
* Participants who are on daily potassium chloride
* Participants who are on diuretics (thiazide or thiazide like diuretics)
* Participants who are pregnant
* Participants who had been diagnosed with any terminal illnesses, visually impaired, disability or mental health related illnesses (visually impaired refers to individuals who self-report to have difficulty reading the wordings on the patient consent form, even with the use of visual aids)
* Participants who are not clinically stable (Clinically stable patients are defined in this study as:
* Has clinic BP 100-160/60-100 mmHg, Heart Rate (HR) 60-100 bpm
* No recent hospitalizations (within the last 3 months) due to hypertensive emergencies, strokes, myocardial infarctions or other acute cardiovascular events
-nil
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Jingfeng
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sun Jingfeng
Family Physician
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Silva-Santos T, Moreira P, Rodrigues M, Padrao P, Pinho O, Norton P, Ndrio A, Goncalves C. Interventions That Successfully Reduced Adults Salt Intake-A Systematic Review. Nutrients. 2021 Dec 21;14(1):6. doi: 10.3390/nu14010006.
Cheong SM, Ambak R, Othman F, He FJ, Salleh R, Mohd Sallehudin S, Palaniveloo L, Ganapathy SS. Knowledge, perception, and practice related to sodium intake among Malaysian adults: findings from the Malaysian Community Salt Study (MyCoSS). J Health Popul Nutr. 2021 May 31;40(Suppl 1):5. doi: 10.1186/s41043-021-00231-4.
Chan CMJ, Dickens BSL, Chong MF. Understanding knowledge, attitudes and behaviours related to dietary sodium intake in a multi-ethnic population in Singapore. Public Health Nutr. 2023 Dec;26(12):2802-2814. doi: 10.1017/S1368980023002422. Epub 2023 Nov 3.
Aaron KJ, Sanders PW. Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence. Mayo Clin Proc. 2013 Sep;88(9):987-95. doi: 10.1016/j.mayocp.2013.06.005.
Ekmekcioglu C, Elmadfa I, Meyer AL, Moeslinger T. The role of dietary potassium in hypertension and diabetes. J Physiol Biochem. 2016 Mar;72(1):93-106. doi: 10.1007/s13105-015-0449-1. Epub 2015 Dec 3.
Koh J, Ang G, Tan KB, Chen C. The social cost of high sodium diet in Singapore. Br J Nutr. 2023 May 14;129(9):1598-1606. doi: 10.1017/S0007114522001568. Epub 2022 May 26.
Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010 Feb 18;362(7):590-9. doi: 10.1056/NEJMoa0907355. Epub 2010 Jan 20.
Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep;54(3):475-81. doi: 10.1161/HYPERTENSIONAHA.109.131235. Epub 2009 Jul 20.
He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD004937. doi: 10.1002/14651858.CD004937.pub2.
Grillo A, Salvi L, Coruzzi P, Salvi P, Parati G. Sodium Intake and Hypertension. Nutrients. 2019 Aug 21;11(9):1970. doi: 10.3390/nu11091970.
Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007 May 10;356(19):1966-78. doi: 10.1056/NEJMra064486. No abstract available.
Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022 Dec 20;80(25):2361-2371. doi: 10.1016/j.jacc.2022.11.005. Epub 2022 Nov 9. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHP-CG-CRGNov24-A05
Identifier Type: OTHER
Identifier Source: secondary_id
2025-0006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.